To include your compound in the COVID-19 Resource Center, submit it here.

Adding Up for AD

Stakeholders are optimistic that Alzheimer's disease funding is on the rise

A year after world health leaders set a goal to find a disease-modifying therapy for dementia by 2025, not-for-profit groups and academics are keeping the pressure on governments and industry to stay in the game and continue supporting new initiatives. Funding, new regulations and target discovery remain the top issues to address, but those pushing for change are starting to see the field galvanize and believe their efforts are beginning to pay off."2014 is going to be looked at as a real turning point for dementia and Alzheimer's disease. We are seeing palpable energy around this disease that was not there two or three years ago," George Vradenburg told BioCentury. "That can help turn political unity into new investments, new investments into new science, and new science into marketed products with regulation and reimbursement."


Read the full 1342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers